Debjit Chattopadhyay
Stock Analyst at Guggenheim
(4.18)
# 429
Out of 5,182 analysts
118
Total ratings
55.86%
Success rate
12.46%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Debjit Chattopadhyay
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CNTA Centessa Pharmaceuticals | Downgrades: Neutral | n/a | $39.57 | - | 9 | Apr 2, 2026 | |
| SLDB Solid Biosciences | Initiates: Buy | $26 | $7.13 | +264.66% | 1 | Mar 20, 2026 | |
| MAZE Maze Therapeutics | Maintains: Buy | $46 → $58 | $27.17 | +113.47% | 4 | Mar 4, 2026 | |
| KRYS Krystal Biotech | Maintains: Buy | $224 → $284 | $266.04 | +6.75% | 5 | Feb 25, 2026 | |
| BMRN BioMarin Pharmaceutical | Maintains: Buy | $106 → $86 | $54.06 | +59.08% | 5 | Feb 25, 2026 | |
| NAMS NewAmsterdam Pharma Company | Maintains: Buy | $41 → $45 | $28.43 | +58.28% | 2 | Feb 19, 2026 | |
| PEPG PepGen | Maintains: Buy | $6 → $7 | $1.75 | +300.00% | 3 | Feb 18, 2026 | |
| TRDA Entrada Therapeutics | Initiates: Buy | $20 | $14.50 | +37.93% | 1 | Feb 11, 2026 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $64 → $52 | $24.77 | +109.93% | 4 | Jan 5, 2026 | |
| RZLT Rezolute | Maintains: Buy | $15 → $6 | $3.30 | +81.82% | 4 | Dec 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $39 | $29.44 | +32.47% | 1 | Dec 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $19 | $21.49 | -11.59% | 7 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $5.77 | +419.93% | 1 | Oct 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $95 | $19.13 | +396.60% | 7 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $90 → $92 | $75.27 | +22.23% | 6 | Sep 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $106 | $52.87 | +100.49% | 5 | Aug 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $10 | $4.97 | +101.21% | 3 | Aug 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $45 → $14 | $13.26 | +5.58% | 3 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $558 → $546 | $423.92 | +28.80% | 8 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $50 | $17.39 | +187.52% | 5 | Jun 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $78 → $55 | $30.70 | +79.15% | 3 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $3.41 | +427.86% | 3 | Dec 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $17 | $11.95 | +42.26% | 2 | Dec 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | n/a | $51.63 | - | 1 | Jun 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $19 | $7.28 | +160.99% | 2 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $3.76 | +485.11% | 1 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $29 | $2.15 | +1,248.84% | 1 | Nov 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $296.11 | - | 1 | Jun 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $6.33 | +342.34% | 1 | Dec 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $20 | $7.32 | +173.22% | 2 | Dec 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $270 → $123 | $27.99 | +339.44% | 8 | Aug 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $54 | $26.61 | +102.93% | 3 | Jul 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $60 | $1.57 | +3,721.66% | 3 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $28.16 | - | 3 | Jun 26, 2017 |
Centessa Pharmaceuticals
Apr 2, 2026
Downgrades: Neutral
Price Target: n/a
Current: $39.57
Upside: -
Solid Biosciences
Mar 20, 2026
Initiates: Buy
Price Target: $26
Current: $7.13
Upside: +264.66%
Maze Therapeutics
Mar 4, 2026
Maintains: Buy
Price Target: $46 → $58
Current: $27.17
Upside: +113.47%
Krystal Biotech
Feb 25, 2026
Maintains: Buy
Price Target: $224 → $284
Current: $266.04
Upside: +6.75%
BioMarin Pharmaceutical
Feb 25, 2026
Maintains: Buy
Price Target: $106 → $86
Current: $54.06
Upside: +59.08%
NewAmsterdam Pharma Company
Feb 19, 2026
Maintains: Buy
Price Target: $41 → $45
Current: $28.43
Upside: +58.28%
PepGen
Feb 18, 2026
Maintains: Buy
Price Target: $6 → $7
Current: $1.75
Upside: +300.00%
Entrada Therapeutics
Feb 11, 2026
Initiates: Buy
Price Target: $20
Current: $14.50
Upside: +37.93%
Ultragenyx Pharmaceutical
Jan 5, 2026
Maintains: Buy
Price Target: $64 → $52
Current: $24.77
Upside: +109.93%
Rezolute
Dec 12, 2025
Maintains: Buy
Price Target: $15 → $6
Current: $3.30
Upside: +81.82%
Dec 4, 2025
Maintains: Buy
Price Target: $32 → $39
Current: $29.44
Upside: +32.47%
Nov 5, 2025
Maintains: Buy
Price Target: $22 → $19
Current: $21.49
Upside: -11.59%
Oct 15, 2025
Initiates: Buy
Price Target: $30
Current: $5.77
Upside: +419.93%
Sep 25, 2025
Maintains: Buy
Price Target: $28 → $95
Current: $19.13
Upside: +396.60%
Sep 23, 2025
Maintains: Buy
Price Target: $90 → $92
Current: $75.27
Upside: +22.23%
Aug 27, 2025
Reiterates: Buy
Price Target: $106
Current: $52.87
Upside: +100.49%
Aug 14, 2025
Maintains: Buy
Price Target: $40 → $10
Current: $4.97
Upside: +101.21%
Aug 13, 2025
Maintains: Buy
Price Target: $45 → $14
Current: $13.26
Upside: +5.58%
Aug 6, 2025
Maintains: Buy
Price Target: $558 → $546
Current: $423.92
Upside: +28.80%
Jun 18, 2025
Reiterates: Buy
Price Target: $50
Current: $17.39
Upside: +187.52%
May 7, 2025
Maintains: Buy
Price Target: $78 → $55
Current: $30.70
Upside: +79.15%
Dec 3, 2024
Reiterates: Buy
Price Target: $18
Current: $3.41
Upside: +427.86%
Dec 3, 2024
Reiterates: Buy
Price Target: $17
Current: $11.95
Upside: +42.26%
Jun 28, 2024
Assumes: Neutral
Price Target: n/a
Current: $51.63
Upside: -
Apr 30, 2024
Initiates: Buy
Price Target: $19
Current: $7.28
Upside: +160.99%
Mar 26, 2024
Initiates: Buy
Price Target: $22
Current: $3.76
Upside: +485.11%
Nov 21, 2022
Maintains: Buy
Price Target: $43 → $29
Current: $2.15
Upside: +1,248.84%
Jun 27, 2022
Downgrades: Neutral
Price Target: n/a
Current: $296.11
Upside: -
Dec 16, 2021
Initiates: Buy
Price Target: $28
Current: $6.33
Upside: +342.34%
Dec 15, 2020
Assumes: Buy
Price Target: $20
Current: $7.32
Upside: +173.22%
Aug 24, 2020
Downgrades: Neutral
Price Target: $270 → $123
Current: $27.99
Upside: +339.44%
Jul 9, 2020
Maintains: Buy
Price Target: $60 → $54
Current: $26.61
Upside: +102.93%
Dec 3, 2019
Downgrades: Neutral
Price Target: $60
Current: $1.57
Upside: +3,721.66%
Jun 26, 2017
Downgrades: Neutral
Price Target: n/a
Current: $28.16
Upside: -